c O M M e n ta rY
In a study published in The Journal of the American Medical Association, Lu-Yao et al. 1 have investigated the effect of primary androgen deprivation therapy (PADT) on prostate-cancer-specific and overall survival in elderly (aged ≥66 years) men with localized prostate cancer. This trial compared patients treated with PADT (started within 180 days after diagnosis, with no surgery or radiation therapy given during this period) with those who received conservative treatment (no definitive treatment during the 180 days after diagnosis). Instrumental variable analysis was used to control for both measured and unmeasured confounding variables. Of a total of 19,271 patients with localized prostate cancer, 41% received PADT and the remainder was managed conservatively. During the follow-up period, 1,560 patients died of prostate cancer and 11,045 deaths from all causes were reported. PADT was associated with lower prostate-cancer-specific survival than was conservative management, with similar overall survival. In the subgroup of patients with poorly differentiated cancer, PADT was associated with improved prostate-cancer-specific SUMMARY This Practice Point commentary discusses the study by Lu-Yao et al. in which primary androgen deprivation therapy (PADT) was compared with conservative treatment in elderly men with localized prostate cancer. Overall, PADT was associated with worse cancer-specific survival than conservative management; however, in the subgroup of patients with poorly differentiated cancer, PADT was associated with improved cancer-specific survival. Although the authors defined conservative treatment as no definitive treatment during the 180 days after diagnosis, many patients in the conservative treatment group would have subsequently received definite treatments, including surgery or radiation therapy. The results of this study, therefore, do not necessarily demonstrate inferiority of PADT to conservative treatment. Accurate evaluation of the efficacy of PADT is confounded by a number of factors, such as the type of androgen deprivation therapy used. Efforts should be made to reduce the adverse effects of androgen deprivation therapy because a high proportion of patients actively choose this treatment modality as primary therapy.
keywords androgen deprivation therapy, conservative treatment, localized prostate cancer, overall survival, prostate-cancer-specific survival survival compared with conservative management, and a borderline improvement in overall survival. On the basis of the above results, the authors concluded that among the majority of elderly men with localized prostate cancer PADT was not associated with better survival than was conservative management.
The role of PADT in localized prostate cancer has not been well defined. Data on the current treatment of prostate cancer in Japan show that PADT is chosen for localized prostate cancer in an extremely high proportion of cases. 2 The US Cancer of the Prostate Strategic Urologic Research Endeavor (CaPSURE) database has also shown increasing use of PADT for localized prostate cancer in recent years. There is growing concern, therefore, that PADT is being applied without clear evidence to support its use, particularly as androgen deprivation therapy (ADT) has been associated with considerable cardiovascular and bone morbidity.
Although Lu-Yao et al. inferred that PADT was inferior to conservative therapy for the treatment of localized prostate cancer, this conclusion has some limitations. The authors defined the PADT group as patients who received PADT during the first 180 days after diagnosis, and the conservative treatment group as those who did not receive surgery, radiation therapy, or ADT during this period. A large number of patients in the latter group, however, might have received definitive treatments, including radical prostatectomy or radiation therapy, after 180 days. Indeed, one study has shown that approximately half of patients managed by watchful waiting receive such treatments within 5 years. 3 Similarly, LuYao et al. do not report what proportion of the PADT group received definitive treatment after 180 days. The results indicating that the PADT group had lower prostate-cancer-specific survival and similar overall survival compared with the conservative management group do not, therefore, necessarily demonstrate inferiority of PADT to conservative treatment.
The authors explained the poor cancer-specific survival in the subgroup of patients with moderately differentiated cancer who received PADT by suggesting that in these patients PADT might have resulted in overgrowth of more-rapidly growing malignant clones. Unfortunately, such a hypothesis is unlikely to be tested in the clinical setting. Kitagawa et al. 4 investigated the clinical and pathological effects of ADT by using tissue specimens from patients treated with radical prostatectomy after neoadjuvant ADT. More than 40% of specimens showed complete histological cure (no cancer cells or complete apoptosis) or near cure (more than half of cancer cells apoptotic). In addition, recurrence-free survival for patients with histologically cured specimens was 100%. These results support the possibility of longterm control or cure by PADT alone in some patients with localized prostate cancer. 5, 6 Any evaluation of the Lu-Yao et al. study should stress that the PADT-treated subgroup with poorly differentiated cancer demonstrated improved prostate-cancer-specific survival.
Currently, little high-quality evidence regarding comparative efficacy and adverse effects is available to guide patients who are selecting treatments for localized prostate cancer. 7 Accurate evaluation of the efficacy of PADT is especially difficult, because many factors-such as type of ADT (i.e. combined androgen blockade, castration monotherapy or antiandrogen therapy), duration of ADT, and ethnicity-affect the outcome of therapy. Most patients, therefore, select a particular treatment on the basis of their own feelings; such decisions can be influenced by many factors, including perceptions of efficacy and adverse effects, and level of patient anxiety. Although clinical practice guidelines, and most urologists, do not recommend PADT as treatment for localized prostate cancer, many patients actively select this form of therapy. We should consider why so many patients select PADT even after receiving accurate, comprehensive explanations from their attending physicians to aid in treatment decision making. Medical treatment, such as PADT, is probably more acceptable to some patients than more-invasive treatment, such as surgery. In addition, physicians themselves might acquiesce to patients' wishes, perhaps because these clinicians have previously seen successful outcomes with PADT. The Prostate Cancer Outcomes Study 8 of patient satisfaction and adverse effects of treatment yielded interesting results; satisfaction was higher in men who received early intervention, including PADT, than in those who were managed expectantly. In addition, most patients said they would make the same choice if they had to select treatment again. As a result, physicians must be able to adequately monitor and reduce potential complications associated with each available treatment modality.
